Global Cervical Cancer Vaccines

Cervical Cancer Vaccines Comprehensive Study by Type (Gardasil, Gardasil 9, Cervarix), Application (Prostate cancer, Cervical cancer, Other), Distribution Channel (Hospitals, Clinics, Others), Treatment Method (Preventive vaccine, Therapeutic vaccine) Players and Region - Global Market Outlook to 2026

Cervical Cancer Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Cervical Cancer Vaccine is also known as human papillomavirus (HPV) it is vaccine that protects against some forms of cancer-causing HPV. Cervical is designed to protect against HPV types 16 and 18, which are responsible for roughly 70% of cervical cancer cases. These kinds are also responsible for the majority of HPV-related genital and head and neck malignancies. Clinical investigations also revealed some cross-reactive protection against virus strains 45 and 31.Cervarix also includes AS04, and unique adjuvant that has been shown to improve immune system response for extended periods of time. Cervical cancer vaccine have some side effects, including soreness and redness at the injection site, fatigue, dizziness, headaches, nausea and vomiting.This growth is primarily driven by Increase in the number of positive cases of cervical cancer.

Globally, a noticeable market trend is evident Introduction to new techniques. Major Players, such as Merck & Co. Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Sanofi (France), AstraZeneca PLC (United Kingdom) and Bristol (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

In 2021, Merck Announces Completion of Organon & Co. Spinoff. Merck’s goal with the spinoff was to create two patient-focused companies with enhanced strategic and operational focus, improved agility, simplified operating models, optimized capital structures and improved financial profiles. Merck believes the transaction will deliver significant benefits for both Merck and Organon and create value for Merck shareholders. The spinoff is expected to allow Merck to increase its focus on key growth pillars, achieve higher revenue and EPS growth rates and enable incremental operating efficiencies of approximately USD 1.5 billion, which are expected to be achieved ratably over three years, with approximately USD 500 million realized during 2021. In connection with the spinoff, Merck received a distribution from Organon of approximately USD 9 billion.

Market Drivers
  • Increase in the number of positive cases of cervical cancer

Market Trend
  • Introduction to new techniques

Restraints
  • Side effects of vaccine to the immune response

Opportunities
Rising focus on immunization programs in emerging countries
Challenges
Lack of availability of skilled labors

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Cervical Cancer Vaccines Study Sheds Light on
— The Cervical Cancer Vaccines Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Cervical Cancer Vaccines industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Cervical Cancer Vaccines industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Gardasil
  • Gardasil 9
  • Cervarix
By Application
  • Prostate cancer
  • Cervical cancer
  • Other
By Distribution Channel
  • Hospitals
  • Clinics
  • Others

By Treatment Method
  • Preventive vaccine
  • Therapeutic vaccine

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the number of positive cases of cervical cancer
    • 3.3. Market Challenges
      • 3.3.1. Lack of availability of skilled labors
    • 3.4. Market Trends
      • 3.4.1. Introduction to new techniques
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cervical Cancer Vaccines, by Type, Application, Distribution Channel, Treatment Method and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cervical Cancer Vaccines (Value)
      • 5.2.1. Global Cervical Cancer Vaccines by: Type (Value)
        • 5.2.1.1. Gardasil
        • 5.2.1.2. Gardasil 9
        • 5.2.1.3. Cervarix
      • 5.2.2. Global Cervical Cancer Vaccines by: Application (Value)
        • 5.2.2.1. Prostate cancer
        • 5.2.2.2. Cervical cancer
        • 5.2.2.3. Other
      • 5.2.3. Global Cervical Cancer Vaccines by: Distribution Channel (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global Cervical Cancer Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cervical Cancer Vaccines (Price)
      • 5.3.1. Global Cervical Cancer Vaccines by: Type (Price)
  • 6. Cervical Cancer Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co. Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca PLC (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bristol (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
  • 7. Global Cervical Cancer Vaccines Sale, by Type, Application, Distribution Channel, Treatment Method and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cervical Cancer Vaccines (Value)
      • 7.2.1. Global Cervical Cancer Vaccines by: Type (Value)
        • 7.2.1.1. Gardasil
        • 7.2.1.2. Gardasil 9
        • 7.2.1.3. Cervarix
      • 7.2.2. Global Cervical Cancer Vaccines by: Application (Value)
        • 7.2.2.1. Prostate cancer
        • 7.2.2.2. Cervical cancer
        • 7.2.2.3. Other
      • 7.2.3. Global Cervical Cancer Vaccines by: Distribution Channel (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global Cervical Cancer Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cervical Cancer Vaccines (Price)
      • 7.3.1. Global Cervical Cancer Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cervical Cancer Vaccines: by Type(USD Million)
  • Table 2. Cervical Cancer Vaccines Gardasil , by Region USD Million (2015-2020)
  • Table 3. Cervical Cancer Vaccines Gardasil 9 , by Region USD Million (2015-2020)
  • Table 4. Cervical Cancer Vaccines Cervarix , by Region USD Million (2015-2020)
  • Table 5. Cervical Cancer Vaccines: by Application(USD Million)
  • Table 6. Cervical Cancer Vaccines Prostate cancer , by Region USD Million (2015-2020)
  • Table 7. Cervical Cancer Vaccines Cervical cancer , by Region USD Million (2015-2020)
  • Table 8. Cervical Cancer Vaccines Other , by Region USD Million (2015-2020)
  • Table 9. Cervical Cancer Vaccines: by Distribution Channel(USD Million)
  • Table 10. Cervical Cancer Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 11. Cervical Cancer Vaccines Clinics , by Region USD Million (2015-2020)
  • Table 12. Cervical Cancer Vaccines Others , by Region USD Million (2015-2020)
  • Table 13. South America Cervical Cancer Vaccines, by Country USD Million (2015-2020)
  • Table 14. South America Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 15. South America Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 16. South America Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 17. South America Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 18. Brazil Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 19. Brazil Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 20. Brazil Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 21. Brazil Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 22. Argentina Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 23. Argentina Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 24. Argentina Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 26. Rest of South America Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 27. Rest of South America Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 28. Rest of South America Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 29. Rest of South America Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 30. Asia Pacific Cervical Cancer Vaccines, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 34. Asia Pacific Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 35. China Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 36. China Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 37. China Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 38. China Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 39. Japan Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 40. Japan Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 41. Japan Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 42. Japan Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 43. India Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 44. India Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 45. India Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 46. India Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 47. South Korea Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 48. South Korea Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 49. South Korea Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 50. South Korea Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 51. Taiwan Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 52. Taiwan Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 53. Taiwan Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 54. Taiwan Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 55. Australia Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 56. Australia Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 57. Australia Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 58. Australia Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 62. Rest of Asia-Pacific Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 63. Europe Cervical Cancer Vaccines, by Country USD Million (2015-2020)
  • Table 64. Europe Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 65. Europe Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 66. Europe Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 67. Europe Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 68. Germany Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 69. Germany Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 70. Germany Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 71. Germany Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 72. France Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 73. France Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 74. France Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 75. France Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 76. Italy Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 77. Italy Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 78. Italy Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 79. Italy Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 80. United Kingdom Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 81. United Kingdom Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 82. United Kingdom Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 83. United Kingdom Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 84. Netherlands Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 85. Netherlands Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 86. Netherlands Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 87. Netherlands Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 88. Rest of Europe Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 89. Rest of Europe Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 90. Rest of Europe Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 91. Rest of Europe Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 92. MEA Cervical Cancer Vaccines, by Country USD Million (2015-2020)
  • Table 93. MEA Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 94. MEA Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 95. MEA Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 96. MEA Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 97. Middle East Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 98. Middle East Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 99. Middle East Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 100. Middle East Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 101. Africa Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 102. Africa Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 103. Africa Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 104. Africa Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 105. North America Cervical Cancer Vaccines, by Country USD Million (2015-2020)
  • Table 106. North America Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 107. North America Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 108. North America Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 109. North America Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 110. United States Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 111. United States Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 112. United States Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 113. United States Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 114. Canada Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 115. Canada Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 116. Canada Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 117. Canada Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 118. Mexico Cervical Cancer Vaccines, by Type USD Million (2015-2020)
  • Table 119. Mexico Cervical Cancer Vaccines, by Application USD Million (2015-2020)
  • Table 120. Mexico Cervical Cancer Vaccines, by Distribution Channel USD Million (2015-2020)
  • Table 121. Mexico Cervical Cancer Vaccines, by Treatment Method USD Million (2015-2020)
  • Table 122. Cervical Cancer Vaccines: by Type(USD/Units)
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Cervical Cancer Vaccines: by Type(USD Million)
  • Table 129. Cervical Cancer Vaccines Gardasil , by Region USD Million (2021-2026)
  • Table 130. Cervical Cancer Vaccines Gardasil 9 , by Region USD Million (2021-2026)
  • Table 131. Cervical Cancer Vaccines Cervarix , by Region USD Million (2021-2026)
  • Table 132. Cervical Cancer Vaccines: by Application(USD Million)
  • Table 133. Cervical Cancer Vaccines Prostate cancer , by Region USD Million (2021-2026)
  • Table 134. Cervical Cancer Vaccines Cervical cancer , by Region USD Million (2021-2026)
  • Table 135. Cervical Cancer Vaccines Other , by Region USD Million (2021-2026)
  • Table 136. Cervical Cancer Vaccines: by Distribution Channel(USD Million)
  • Table 137. Cervical Cancer Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 138. Cervical Cancer Vaccines Clinics , by Region USD Million (2021-2026)
  • Table 139. Cervical Cancer Vaccines Others , by Region USD Million (2021-2026)
  • Table 140. South America Cervical Cancer Vaccines, by Country USD Million (2021-2026)
  • Table 141. South America Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 142. South America Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 143. South America Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 144. South America Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 145. Brazil Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 146. Brazil Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 147. Brazil Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 148. Brazil Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 149. Argentina Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 150. Argentina Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 151. Argentina Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 152. Argentina Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 153. Rest of South America Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 154. Rest of South America Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 155. Rest of South America Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 156. Rest of South America Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 157. Asia Pacific Cervical Cancer Vaccines, by Country USD Million (2021-2026)
  • Table 158. Asia Pacific Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 159. Asia Pacific Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 160. Asia Pacific Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 161. Asia Pacific Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 162. China Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 163. China Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 164. China Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 165. China Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 166. Japan Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 167. Japan Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 168. Japan Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 169. Japan Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 170. India Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 171. India Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 172. India Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 173. India Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 174. South Korea Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 175. South Korea Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 176. South Korea Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 177. South Korea Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 178. Taiwan Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 179. Taiwan Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 180. Taiwan Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 181. Taiwan Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 182. Australia Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 183. Australia Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 184. Australia Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 185. Australia Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 186. Rest of Asia-Pacific Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 187. Rest of Asia-Pacific Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 188. Rest of Asia-Pacific Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 189. Rest of Asia-Pacific Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 190. Europe Cervical Cancer Vaccines, by Country USD Million (2021-2026)
  • Table 191. Europe Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 192. Europe Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 193. Europe Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 194. Europe Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 195. Germany Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 196. Germany Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 197. Germany Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 198. Germany Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 199. France Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 200. France Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 201. France Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 202. France Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 203. Italy Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 204. Italy Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 205. Italy Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 206. Italy Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 207. United Kingdom Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 208. United Kingdom Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 209. United Kingdom Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 210. United Kingdom Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 211. Netherlands Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 212. Netherlands Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 213. Netherlands Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 214. Netherlands Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 215. Rest of Europe Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 216. Rest of Europe Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 217. Rest of Europe Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 218. Rest of Europe Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 219. MEA Cervical Cancer Vaccines, by Country USD Million (2021-2026)
  • Table 220. MEA Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 221. MEA Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 222. MEA Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 223. MEA Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 224. Middle East Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 225. Middle East Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 226. Middle East Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 227. Middle East Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 228. Africa Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 229. Africa Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 230. Africa Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 231. Africa Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 232. North America Cervical Cancer Vaccines, by Country USD Million (2021-2026)
  • Table 233. North America Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 234. North America Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 235. North America Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 236. North America Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 237. United States Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 238. United States Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 239. United States Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 240. United States Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 241. Canada Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 242. Canada Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 243. Canada Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 244. Canada Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 245. Mexico Cervical Cancer Vaccines, by Type USD Million (2021-2026)
  • Table 246. Mexico Cervical Cancer Vaccines, by Application USD Million (2021-2026)
  • Table 247. Mexico Cervical Cancer Vaccines, by Distribution Channel USD Million (2021-2026)
  • Table 248. Mexico Cervical Cancer Vaccines, by Treatment Method USD Million (2021-2026)
  • Table 249. Cervical Cancer Vaccines: by Type(USD/Units)
  • Table 250. Research Programs/Design for This Report
  • Table 251. Key Data Information from Secondary Sources
  • Table 252. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cervical Cancer Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Cervical Cancer Vaccines: by Application USD Million (2015-2020)
  • Figure 6. Global Cervical Cancer Vaccines: by Distribution Channel USD Million (2015-2020)
  • Figure 7. South America Cervical Cancer Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Cervical Cancer Vaccines Share (%), by Country
  • Figure 9. Europe Cervical Cancer Vaccines Share (%), by Country
  • Figure 10. MEA Cervical Cancer Vaccines Share (%), by Country
  • Figure 11. North America Cervical Cancer Vaccines Share (%), by Country
  • Figure 12. Global Cervical Cancer Vaccines: by Type USD/Units (2015-2020)
  • Figure 13. Global Cervical Cancer Vaccines share by Players 2020 (%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 16. Merck & Co. Inc. (United States) Revenue: by Geography 2020
  • Figure 17. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 18. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2020
  • Figure 21. AstraZeneca PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 22. AstraZeneca PLC (United Kingdom) Revenue: by Geography 2020
  • Figure 23. Bristol (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bristol (United States) Revenue: by Geography 2020
  • Figure 25. Global Cervical Cancer Vaccines: by Type USD Million (2021-2026)
  • Figure 26. Global Cervical Cancer Vaccines: by Application USD Million (2021-2026)
  • Figure 27. Global Cervical Cancer Vaccines: by Distribution Channel USD Million (2021-2026)
  • Figure 28. South America Cervical Cancer Vaccines Share (%), by Country
  • Figure 29. Asia Pacific Cervical Cancer Vaccines Share (%), by Country
  • Figure 30. Europe Cervical Cancer Vaccines Share (%), by Country
  • Figure 31. MEA Cervical Cancer Vaccines Share (%), by Country
  • Figure 32. North America Cervical Cancer Vaccines Share (%), by Country
  • Figure 33. Global Cervical Cancer Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Merck & Co. Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Sanofi (France)
  • AstraZeneca PLC (United Kingdom)
  • Bristol (United States)
Select User Access Type

Key Highlights of Report


Jan 2022 200 Pages 89 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cervical Cancer Vaccines Quantitative research analysis
Global Cervical Cancer Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Cervical Cancer Vaccines Market are Merck & Co. Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Sanofi (France), AstraZeneca PLC (United Kingdom) and Bristol (United States) etc.
Cervical Cancer Vaccine is also known as human papillomavirus (HPV) it is vaccine that protects against some forms of cancer-causing HPV. Cervical is designed to protect against HPV types 16 and 18, which are responsible for roughly 70% of cervical cancer cases. These kinds are also responsible for the majority of HPV-related genital and head and neck malignancies. Clinical investigations also revealed some cross-reactive protection against virus strains 45 and 31.Cervarix also includes AS04, and unique adjuvant that has been shown to improve immune system response for extended periods of time. Cervical cancer vaccine have some side effects, including soreness and redness at the injection site, fatigue, dizziness, headaches, nausea and vomiting.

Know More About Global Cervical Cancer Vaccines Report?

Have a Query? Click Here

Other Related Reports

Pharma E-commerce Comprehensive Study by Type (Rx (prescription medicine), OTC (over the counter)), Application (Individual Use, Industrial Use) Players and Region - Global Market Outlook to 2028
$ 3500
Medical Packaging Solutions Comprehensive Study by Type (-Primary Packaging, Blister Pack, Pouches, Bottles & Container, Others, -Secondary Packaging, Folding Cartons, Paperboard, Trays, Others, -Ter...
$ 3450
Remdesivir Medicine Comprehensive Study by Application (Ebola Virus Disease, Marburg Virus Infection, Possible COVID-19 Treatment), Administration (Oral, Intravenous), End-users (Hospitals, Clinics, ...
$ 3450
Pneumonia Tablets Comprehensive Study by Type (Branded, Generic), Application (Children, Youth, Adults, Seniors), Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy) Players an...
$ 3500
Coronavirus Vaccine Investment Comprehensive Study by Type (Government, Private Firms), Application (Hospitals, Research Laboratories, Clinics, Others) Players and Region - Global Market Outlook to 2...
$ 3500
Vincamine Comprehensive Study by Form (Vincamine Tablets, Vincamine Capsules, Vincamine Infusion/Injection), Distribution Channel (Hospital Pharmacy, Individual Pharmacy, Online Pharmacy), Dosage (Vi...
$ 3650